Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR–Mutated Lung Cancer

Introduction: The mutation rate of T790M might change the effective therapeutic sequence of EGFR tyrosine kinase inhibitors (TKIs). This simulation estimates the T790M positivity rate required for first-line first- or second-generation EGFR TKI to exceed overall progression-free survival (PFS) of fi...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Naoki Haratake, MD, PhD, Toshihiro Misumi, PhD, Takeharu Yamanaka, PhD, Takashi Seto, MD, PhD
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2020-11-01
coleção:	JTO Clinical and Research Reports
Assuntos:	Non–small cell lung cancer EGFR Sequential treatment Rebiopsy T790M
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2666364320301089
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!